Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/6/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Pfizer (PFE) Tops Q4 EPS by 28c, Tops on Revenue; Offers Guidance
January 30, 2024 6:46 AM ESTPfizer (NYSE: PFE) reported Q4 EPS of $0.10, $0.28 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $14.25 billion versus the consensus estimate of $14.22 billion.
The company reaffirms Full-Year 2024 guidance provided on December 13, 2023, of Revenues of $58.5 to $61.5 Billion and Adjusted... More
